Drug Profile
Research programme: protein therapeutics - aTyr Pharma
Alternative Names: Project ORCALatest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator aTyr Pharma
- Class Antibodies; Proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 14 May 2018 aTyr decides not to proceed with with IND-enabling activities in Solid tumours for ORCA programme
- 31 Dec 2017 aTyr Pharma files for patent protection for protein therapeutics worldwide